Skip to main content

Table 1 Patient characteristics

From: Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

Number of patients, n 69
Follow-up time since inclusion, months (median - IQR) 15 (6–35)
Follow-up time since diagnosis, months (median - IQR) 39 (20.5–108)
Age at diagnosis, years (median - IQR) 53 (41.5 – 60)
Female sex, % (n) 53.6 (37/69)
Stage at inclusion, % (n)
  Local (AJCC stage I & II) 46.4 (32/69)
  Regional (AJCC stage III) 37.7 (26/69)
  Systemic (AJCC stage IV) 15.9 (11/69)
Active disease at inclusion 20.3 (14/69) (3 stage III, 11 stage IV)
Melanoma characteristics
  Breslow (median, IQR) 1.60 (1.08 – 2.60)
  Ulceration, % (n) 35.7 (20/56)
  Sentinel invasion, % (n) 27.1 (16/59)
Location of primary melanoma
  Head & neck, % (n) 10.6 (7/69)
  Trunk, % (n) 39.4 (26/69)
  Extremities, % (n) 50 (33/69)
  Unknown primary 3 (3/69)
  1. IQR, interquartile range; AJCC, American joint committee on cancer.